NCT04988191Unknown1 期
The Efficacy and Safety of Toripalimab Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Patients With Advanced MSI-H or dMMR Colorectal Cancer: an Open-label, Multicenter, Single-arm, Phase Ib/II Study
Peking University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2020年12月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Pathological complete response rate based on blinded, independent, central review
研究概览
简要总结
This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed colorectal adenocarcinoma meeting any of the following criterion: a) T3-4 resectable rectal cancer; b) T1-2 rectal cancer located within 12 cm from the anal verge and refusing direct surgery or radiation therapy; c) T4a-b resectable colon cancer.
- •Microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR).
- •Measurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria and haven't received any local treatment.
- •Eastern Cooperative Oncology Group (ECOG) 0-
- •Fully aware of this study and having signed informed consent.
- •Age 18 to 75 years old without gender limitation.
- •Good compliance.
- •Absolute neutrophil count ≥1500/mm3, platelet ≥100,000/mm3, Hb ≥10g/dl, serum creatinine ≤1.5 times ULN, creatinine clearance rate ≥50mL/min, ALT and AST ≤2.5 times ULN, INR or aPTT ≤1.5 times ULN (INR ≤2 times ULN and aPTT in normal range for patients who are on prophylactic anticoagulant therapy within 14 days before study treatment), total bilirubin level ≤2 times ULN (within 7 days before study treatment).
- •Women of childbearing age should confirm that serum pregnancy test is negative and agree to use effective contraceptive methods during study treatment and the following 60 days.
排除标准
- •Previously received anti-PD1 or anti-PDL1 or anti-PDL2 or anti-CTLA
- •Uncontrolled active bleeding from the primary tumor or intestinal obstruction.
- •Contraindications of bevacizumab or irinotecan.
- •Hypersensitivity to other monoclonal antibodies.
- •Any active, known or suspected autoimmune disease.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites to a moderate or greater extent.
- •History of one of the following dieases: idiopathic pulmonary fibrosis, organized pneumonia (eg. bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia and interstitial pneumonia, or evidence of active pneumonia through enhanced chest CT screening.
- •Major surgery within 4 weeks before enrollment and haven't fully recovered from the previous surgery.
- •Active bleeding or abnormal coagulation (aPTT >43s or INR >1.5 times ULN), or having a tendency to bleed or receiving thrombolytic or anticoagulant therapy.
- •Previously received allogeneic stem cell or parenchymal organ transplantation.
- •Any significant clinical or laboratory abnormality that the investigator considers to influence the safety assessment, eg. uncontrolled active infection, uncontrolled diabetes, hypertension that cannot be reduced to normal range with monotherapy, grade II or above peripheral neuropathy, congestive heart failure, heart disease (class II or higher) as defined by the New York College of Cardiology, myocardial infarction within 3 months prior to enrollment, unstable arrhythmias, unstable angina pectinis, chronic kidney disease, abnormal thyroid function and previous or co-existing malignancies.
- •History of uncorrected serum electrolyte disturbances such as potassium, calcium and magnesium.
- •HIV infection.
- •Active hepatitis B or hepatitis C.
- •Pregnancy or lactation period, or unwilling to use contraception during the trial.
- •With other malignancy within 5 year, except cervical carcinoma in situ, basal or squamous skin cancer, local prostatic carcinoma and ductal carcinoma in situ.
- •Use corticosteroids (dose of prednisone or similar drugs> 10mg/day) or other immunosuppressive agents within 14 days before enrollment.
- •Patients with active tuberculosis (TB) who are receiving anti-TB treatment or have received anti-TB treatment within 1 year.
- •Active infection, or treatment with oral or intravenous antibiotics within the first 2 weeks prior to neoadjuvant therapy, except prophylactic administration.
- •Anti-infective vaccine (eg. influenza vaccine, varicella vaccine, etc.) injection within 4 weeks before neoadjuvant therapy.
- •Previous participation in other clinical trials within 4 weeks before neoadjuvant therapy.
- •Any other disease, metabolic disorder, abnormal physical examination or abnormal laboratory results that may contrainn the use of trial drug, or affect the reliability of study results, or lead to high risk of treatment complications, or affect patient compliance.
研究组 & 干预措施
Toripalimab combined with bevacizumab and chemotherapy
Experimental
干预措施: Toripalimab (Drug)
Toripalimab combined with bevacizumab and chemotherapy
Experimental
干预措施: Bevacizumab (Drug)
Toripalimab combined with bevacizumab and chemotherapy
Experimental
干预措施: Irinotecan (Drug)
结局指标
主要结局
Pathological complete response rate based on blinded, independent, central review
时间窗: 10 weeks
Percentage of patients who achieve pathological complete response (pCR) based on blinded, independent, central review (BICR).
次要结局
- R0 recession rate(10 weeks)
- Time to surgery(10 weeks)
- Pathological complete response rate assessed by local investigator(10 weeks)
- Objective response rate(Up to 3 years)
- Score of life quality(Until 30 days after the last treatment)
- Pathological complete response rate based on blinded, independent, central review (BICR) and the assessment of local investigator(10 weeks)
- Tumor regression grade (TRG)(10 weeks)
- Event free survival(Up to 3 years)
- Disease-free survival(Up to 3 years)
- One-year or two-year disease-free survival rate(Up to 2 years)
- One-year or two-year overall survival rate(Up to 2 years)
- Incidence of Treatment-Related Adverse Events(Until 30 days after the last treatment)
研究者
Shen Lin
Professor
Peking University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerTNBC - Triple-Negative Breast CancerBreast CancerNCT05491694The First Affiliated Hospital with Nanjing Medical University20
Unknown
2 期
Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaNCT04888403The First Affiliated Hospital of Zhengzhou University45
进行中（未招募）
2 期
Toripalimab Combined With SBRT for NSCLCNon-small Lung CancerNCT06293690Shanghai Pulmonary Hospital, Shanghai, China40
撤回
3 期
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaLocally Advanced or Metastatic Urothelial CarcinomaNCT04568304Shanghai Junshi Bioscience Co., Ltd.364
招募中
1 期
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIbTransformed LymphomaEBV-Positive DLBCL, NosALK-Positive Anaplastic Large Cell LymphomaNCT04058470Huiqiang Huang140